Detailed performance report for TEVA PHARMACEUTICAL INDUSTRIES LIMITED covering Q2 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.
Summary of Financial Performance: Teva delivered Q2 2026 revenue of about $4.1 billion, down 1% year over year in USD, but underlying performance was strong excluding generic REVLIMID headwinds. Innovative portfolio revenue grew 43%, led by AUSTEDO (+40%), UZEDY (+43%), and AJOVY (+56%). Gross margin improved 80 bps to 55.4%, free cash flow rose 31% to $622 million, and EBITDA/margins benefited from mix shift toward higher-margin innovative products. GAAP net loss was $576 million, largely driven by a $724 million IPR&D charge tied to the Amylyx acquisition.
Company Outlook & Strategy: Management raised full-year revenue guidance for AUSTEDO, UZEDY, and AJOVY, and reiterated confidence in reaching mid-single-digit revenue growth, 30% operating margin by 2027, net debt/EBITDA below 2x, and 80% cash conversion. The core strategy remains the “pivot to growth” through innovation, pipeline execution, biosimilars expansion, and disciplined capital allocation. Teva also highlighted potential for multiple product launches over the next five years and the transition to a direct NYSE ordinary share listing to broaden investor access.
Key Industry Trends: The call emphasized growing demand for long-acting injectables in psychiatry, unmet needs in Tourette syndrome, asthma, vitiligo, celiac disease, and inflammatory bowel disease, and continued biosimilar opportunity as a growth platform. Competitive and pricing pressures remain evident in generics, and the company noted changing purchasing patterns ahead of IRA implementation.
Operational Highlights: AUSTEDO continued strong momentum, with U.S. revenue of $676 million and XR now representing over 60% of new patients. UZEDY gained share rapidly and nearly doubled risperidone LAI share, while AJOVY gained market share in both U.S. and ex-U.S. markets. Teva advanced several pipeline assets: olanzapine LAI is on track for Q4 FDA action and U.S. launch, ecopipam was filed for Tourette syndrome, DARI is moving toward late-stage data, and duvakitug gained two new indications (hidradenitis suppurativa and fibrotic Crohn’s disease). Biosimilars now total 15 marketed products with 14 in pipeline, and the company expects to exceed its $800 million target by 2027.
Challenges & Risks: Generics remained under pressure, down 15% year over year, mainly due to REVLIMID loss and fewer high-value launches, with 2026 expected to be somewhat softer. Management also noted higher planned OpEx to support launches, channel inventory normalization for AUSTEDO, and anticipated Q4 revenue pressure from IRA-related purchasing behavior. Pipeline milestones remain subject to regulatory approvals and clinical/readout risk.
Key Analyst Questions & Responses: The main themes in the discussion centered on sustainability of growth in AUSTEDO, UZEDY, and AJOVY; timing and launch economics for olanzapine LAI; and the strategic value of the newly added duvakitug indications. Management responded that demand trends remain strong, launch sequencing is well planned, and the new indication additions broaden Teva’s addressable markets and reinforce the thesis of a multi-asset innovation-led growth engine.
Access the official earnings call transcript for TEVA-PHARMACEUTICAL-INDUSTRIES-LIMITED 2026 Q2. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.